Metabolic syndrome is associated with disease activity in patients with rheumatoid arthritis

Joint Bone Spine

Volumn 83, Issue 5, 2016, Pages 563-567

  Tantayakom, Pongchirat ^a   Koolvisoot, Ajchara ^a   Arromdee, Emvalee ^a   Chiowchanwisawakit, Praveena ^a   Muangchan, Chayawee ^a   Katchamart, Wanruchada ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

DAS28; Disease activity; Metabolic syndrome; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; ETANERCEPT; FOLIC ACID; GOLD SALT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FUNCTIONAL STATUS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; SMOKING; TOBACCO USE; AGED; CARDIOVASCULAR DISEASE; DISEASE EXACERBATION; PATHOPHYSIOLOGY; REGISTER; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; METABOLIC SYNDROME; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; REGISTRIES; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84970038675     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.10.016     Document Type: Article

References (29)

1. [1] Meune, C., Touze, E., Trinquart, L., et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 48 (2009), 1309–1313.
2. [2] Solomon, D.H., Kremer, J., Curtis, J.R., et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69 (2010), 1920–1925.
3. [3] Micha, R., Imamura, F., Wyler von Ballmoos, M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108 (2011), 1362–1370.
4. [4] Mottillo, S., Filion, K.B., Genest, J., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56 (2010), 1113–1132.
5. [5] Karvounaris, S.A., Sidiropoulos, P.I., Papadakis, J.A., et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 66 (2007), 28–33.
6. [6] Rostom, S., Mengat, M., Lahlou, R., et al. Metabolic syndrome in rheumatoid arthritis: case-control study. BMC Musculoskelet Disord, 14, 2013, 147.
7. [7] Dessein, P.H., Norton, G.R., Joffe, B.I., et al. Metabolic cardiovascular risk burden and atherosclerosis in African black and Caucasian women with rheumatoid arthritis: a cross-sectional study. Clin Exp Rheumatol 31 (2013), 53–61.
8. [8] Lee, S.G., Kim, J.M., Lee, S.H., et al. Is the frequency of metabolic syndrome higher in South Korean women with rheumatoid arthritis than in healthy subjects?. Korean J Intern Med 28 (2013), 206–215.
9. [9] Dao, H.H., Do, Q.T., Sakamoto, J., Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther, 12, 2010, R218.
10. [10] Trayhurn, P., Wood, I.S., Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92 (2004), 347–355.
11. [11] Gremese, E., Ferraccioli, G., The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risks. Autoimmun Rev 10 (2011), 582–589.
12. [12] Baker, J.F., Mehta, N.N., et al. Vitamin D, metabolic dyslipidemia, and metabolic syndrome in rheumatoid arthritis. Am J Med, 125, 2012, 1036 [e9–e15].
13. [13] Haque, U.J., Bathon, J.M., Giles, J.T., Association of vitamin D with cardiometabolic risk factors in rheumatoid arthritis. Arthritis Care Res 64 (2012), 1497–1504.
14. [14] Toms, T.E., Panoulas, V.F., John, H., et al. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60 – more than just an anti-inflammatory effect? A cross-sectional study. Arthritis Res Ther, 11, 2009, R110.
15. [15] Aletaha, D., Neogi, T., Silman, A.J., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 (2010), 2569–2581.
16. [16] Prevoo, M.L., van't Hof, M.A., Kuper, H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995), 44–48.
17. [17] Osiri, M., Deesomchok, U., Tugwell, P., Evaluation of functional ability of Thai patients with rheumatoid arthritis by the use of a Thai version of the Health Assessment Questionnaire. Rheumatology 40 (2001), 555–558.
18. [18] Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002), 3143–3421.
19. [19] Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. National Institutes of Health. Obes Res 6 (1998), 51s–209s.
20. [20] Grundy, S.M., Cleeman, J.I., Daniels, S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005), 2735–2752.
21. [21] WHO Expert Consultation, Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363 (2004), 157–163.
22. [22] Salinas, M.J., Bertoli, A.M., Lema, L., et al. Prevalence and correlates of metabolic syndrome in patients with rheumatoid arthritis in Argentina. J Clin Rheumatol 19 (2013), 439–443.
23. [23] Sahebari, M., Goshayeshi, L., Mirfeizi, Z., et al. Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis. Sci World J 11 (2011), 1195–1205.
24. [24] Crowson, C.S., Myasoedova, E., Davis, J.M., et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 38 (2011), 29–35.
25. [25] Chung, C.P., Oeser, A., Solus, J.F., et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 196 (2008), 756–763.
26. [26] Karakoc, M., Batmaz, I., Sariyildiz, M.A., et al. The relationship of metabolic syndrome with disease activity and the functional status in patients with rheumatoid arthritis. J Clin Med Res 4 (2012), 279–285.
27. [27] Abourazzak, F.E., Mansouri, S., Najdi, A., et al. Prevalence of metabolic syndrome in patients with rheumatoid arthritis in Morocco: a cross-sectional study of 179 cases. Clin Rheumatol 33 (2014), 1549–1555.
28. [28] Zhang, J., Fu, L., Shi, J., et al. The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS One, 8, 2013, e78151.
29. [29] Parra-Salcedo, F., Contreras-Yanez, I., Elias-Lopez, D., et al. Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity. Arthritis Res Ther, 17, 2015, 34.